• Topical steroids

Halog Generic Name & Formulations

General Description

Halcinonide 0.1%; crm, oint.

Pharmacological Class


See Also

    How Supplied

    Crm, oint—30g, 60g, 240g

    Halog Indications


    Corticosteroid-responsive dermatoses.

    Halog Dosage and Administration

    Adults and Children

    Apply to affected areas 2–3 times daily. Discontinue when control is achieved. Do not occlude.

    Halog Contraindications

    Not Applicable

    Halog Boxed Warnings

    Not Applicable

    Halog Warnings/Precautions


    Not for oral, ophthalmic, or intravaginal use. Avoid use on face, axilla, or groin. Do not use on pre-existing skin atrophy. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, use of occlusive dressings, altered skin barrier, liver failure, young age; discontinue gradually, reduce dose, or substitute with less potent corticosteroid if occurs. Treat infection if present; discontinue if infection persists or worsens. Avoid abrupt cessation in chronic use. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.

    Halog Pharmacokinetics

    See Literature

    Halog Interactions

    Halog Adverse Reactions

    Adverse Reactions

    Burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, skin maceration, secondary infection, skin atrophy, striae, miliaria; HPA axis suppression (esp. in children); rare: Cushing's syndrome, hyperglycemia, glucosuria.

    Halog Clinical Trials

    See Literature

    Halog Note

    Not Applicable

    Halog Patient Counseling

    See Literature